Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Doublehead, refer to the rns from the company, link below
https://www.investegate.co.uk/synairgen-plc--sng-/rns/preliminary-results-for-the-year-ended-31-dec-2019/202005260700138353N/
Sparkle, for someone that has been supposedly invested in here so long u know surprisingly little about the company.
Not anyone can manufacture nebuliser interferon, the company has a patent on it.
There are many companies that make nebuliser hospitals use them every single day, nebuliser production should not be a major issue, and even if it does become one then that would not affect the valuation, it would only mean nebuliser companies would step up their game because of the additional demand, like we saw with testing and PPE etc, at first there was a shortage but because of the huge demand other manufacturers stepped in and now those things aren't a problem anymore
Doublehead,
Worth pointing out that 360p finncap valuation is discounted by 50% incase they don't get to market ie. that is what the price should be now.
If this goes to market, which is effectively what regulatory approval would enable it to do,then that 50% discount doesn't apply, putting the price at 720p
It's possible Mike, I can't remember the exact figure but they are already in product and have been for atleast a month or so
As those that know, saw with NCYT a couple of months ago.
If that happens then who know where this opens Monday morning
They've been manufacturing the drug since April, those that have followed the compa y since then will know this.
Those genuine inveators that don't pls go back and watch the 3/ 4 interviews the CEO has done since and also read the RNSs
Those things won't be an issue for Big Pharma they have the cash and the resource to throw at that.
Already happening bebeto, you saw the TR1 FROM polar Capital on Tuesday, others could well be buying all the cheap shares ignorant retail punters are gifting them
The following bits of upcoming news which should happen in fairly short order will all set rockets under the SP again.
-FDA approval
-MHRA approval
-EMA approval
-Other countries regulatory approval
-COPD result due at any point from next week onwards which is what the company was originally all about and has been working on for the past 15 years
-Licensing/buyout
FDA wants to approve drugs that demonstrate even a hint of alleviation 'asap', that is from the FDA EUA website.
Check it yourselves if you don't belive.
According to the CEO, see the bloomberg interview from earlier this week.
Also, SNG is talking to a 'cluster' of Big Pharma.
Bidding war ahoy
Not weeks. Again, if anyone missed my last post on this.
Just look at how long the FDA took to approve Remdeisivr - 3 days.
Furthermore SNGs drug is already proven safe, Interferon, its active ingredient has been used for decades already
Incase anyone missed it the last time I posted it.
Anybody that says otherwise either hasn't done their DD, just check the FDA website and look at Remdeisivirs approval, or is trying for a cheaper entry
Is the price target here, per the broker note, if it turns into a bidding war between Big Pharma then could go even higher
Sparkle - this can be combined with Remdesivir, theres been studies done on IFN and Remdesivir combined and they have shows positive resutls
Rickee, we don't need phase 3 results to get Emergency Use Approval under the FDA.
See my posts from last night. Gilead got FDA approval within two days of top line, I. E non peer reviewed etc, Phase 2 results from Remdesivir.
They announced results c. 28th April and received FDA approval 1st May.
The US is desperate, FDA website itself says "... We will use every available method to move new treatments to patients as quickly as possible..'
See the links on my posts from last night
There's only two treatments in the world right now proven to work for Covid - SNG and Remdesivir. Remd was FDA approved within two days of announcing Phase 2 results and is sold out for the next 3 months. SNG Phase II results reported on Monday are better. Go figure!
NB: Remdesivir added $11BN to Gilead Sciences (the drug developer's) share price when it announced positive results for it's Covid treatment, SNG's current m'cap is <£300M
FDA took 2 days to approve Remdesivir for EUA - topline results announced 29th April, FDA approval granted 1st May.
$SNG #SNG's results are better. Expect approvals to come through 'very quickly' per CEO comments on Bloomberg today.
this is the comment from the latest broker note (finncap) on valuation - note the valuation is discounted by 50% for risk of getting to market so effectively double the below if it gets to market
Valuation.
We raise our target price to 360p (sum-of-the-parts rNPV). It assumes a 50% chance of SNG001 reaching the market. However, it is within the realms of possibility that Synairgen will receive orders from governments ahead of the winter flu season and potential second wave of COVID-19 infections. Based on pricing points for Rebif and Avonex and Gilead’s remdesivir ($2-3,000 per treatment) and the prospect of Synairgen being able to supply up to 1m doses by the end of 2020, it is not inconceivable that an order book of $2-3bn could be generated by the year-end, which would imply a valuation
substantially higher than 360p (c.£0.5bn market cap).